Developing next-generation therapies
to treat neurological disorders
Our fine-tuned drug design approach enables us to precisely treat neurological disorders like Essential Tremor, epilepsy and anxiety
by restoring healthy brain receptor function, without overactivating
Pagliuca
Harvard
Life Lab
OUR STORY
Every member of our team has dedicated their career to developing neuro-medicines for patients. We coalesced to advance scientific innovations that help patients with neurological disorders live longer, healthier lives.
The idea was born at Prof. Kevin Hodgetts' Laboratory for Drug Discovery in Neuroscience at the Brigham and Women's Hospital, when Dr. Hodgetts and Dr. Dario Doller saw the opportunity to harness allosteric modulation to develop a new generation of neurological therapies.
We are now advancing a small molecule therapy to treat Essential Tremor (ET), before targeting epilepsy, anxiety, and other neurological disorders.
Our unique methodology
Brain diseases
We are developing fine-tuned positive allosteric modulators to treat neurological disorders, as small molecules remain the optimal drug modality in this therapeutic area.
Precision approach
We control for biologic risk by focusing on clinically validated biological targets with persistent unmet medical need, mechanistically traced to suboptimal drug functional effects, amenable to allosteric modulation.
Patients first
Our lead small molecule is a GABAA modulator targeting Essential Tremor, fine-tuned to restore healthy receptor function while avoiding excessive receptor potentiation, to preserve efficacy and reduce side-effects
Our Therapy
We have achieved in vivo proof-of-concept in mice, and are now identifying a development candidate to treat Essential Tremor.
Meet the Team
We have dedicated our careers to advancing scientific innovations to help patients live longer, healthier lives.
Our Scientific Advisory Board
Our SAB brings deep expertise at every level of drug development, and is deeply involved in all aspects of Modulate Bio. These industry veterans are dedicated to advancing our compounds to human trials efficiently and effectively
Recognitions
Blavatnik Therapeutic Challenge Award
Our founding lab was awarded $1 million to advance lead compounds in Essential Tremor in 2022-2023
Harvard Business School
Semi-finalists in the 2023 Harvard Business School New Venture Competition pitch competition
Nucleate Activator Program
Semi-finalists in the 2023 Nucleate Activator Program final pitch showcase in Boston
President's Innovation Challenge
Semi-finalists 2023 and Finalists 2024 in Harvard iLab’s President's Innovation Challenge
iLab Grant Award
Awarded a non-dilutive grant by the Harvard Innovation Lab to advance our research and business development in 2023
MIT SHIP Competition
Semi-finalists in the 2024 MIT Sloan Healthcare Innovation Prize,
8 of 300+ teams
Current ET treatments are worse than the disease itself
- Patients, physicians and caregivers struggling with Essential Tremor (ET)
Indication #1: Essential Tremor
Essential Tremor is widespread and highly debilitating
Yet ET remains significantly underreported and undertreated
We are thrilled to advance the first novel treatment to help ET patients, their families and caretakers in over half a century.
Please connect to learn more - we are excited to engage with the ET community!
Get in Touch
Modulate Bio
Pagliuca Harvard Life Lab
127 Western Avenue, Allston, MA 02134